Minerva Neurosciences, Inc.
NERVHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframeMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. The company carries a $211.5M market cap, placing it firmly in the micro-cap category. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Market Cap
$211.5M
Beta
-0.10
P/E (TTM)
—
P/E (Fwd)
-10.55
EPS (TTM)
$-36.12
EPS (Fwd)
$-0.42
ROE
—
ROA
-28.4%
Cash
$75.3M
Total Debt
$60.0M
Free CF
-$8.9M
52W Change
104.2%
Annual Financials
Cash vs Debt
Where NERV stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NERV finished 17.19% below its 150-day moving average ($5.41) and 11.64% below its 200-day moving average ($5.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NERV overbought or oversold?
At the September 3, 2026 close, NERV's RSI(14) was 59.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $75.3M in cash and $60.0M in debt, NERV maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$8.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
The relatively low beta of -0.10 suggests NERV is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Minerva Neurosciences, Inc. and its sector.